Sex and gender differences in comorbidities in spondyloarthritis: a focus on psoriatic arthritis

Objective. Spondyloarthritis is a family of inflammatory diseases subdivided into those affecting the spine, called axial spondyloarthritis, and those involving peripheral joints, such as psoriatic arthritis (PsA). Several studies have reported differences in clinical manifestations, outcomes, and treatment responses between male and female PsA patients. The aim of our review was to evaluate if differences may also be identified in the context of cardiovascular (CV) risk factors and diseases.

Methods. Patients with PsA have a higher CV risk than the general population. The increased CV risk associated with PsA is likely caused by the complex interplay of traditional CV risk factors, chronic systemic inflammation, and side effects related to the use of certain anti-rheumatic drugs.

Results. Sex differences in CV risk factors in PsA patients, according to several studies, are controversial. However, the few studies that reported sex-stratified estimates did not find differences in the risk of stroke and myocardial infarction between sexes. The same also holds true for CV mortality. These mixed results may be related to the different study designs and case definitions, as well as genetic and geographical variability across the investigated populations.

Conclusions. In conclusion, our review suggests that the evaluation of sex-gender aspects of CV comorbidities in PsA should be a central step in the context of personalized medicine in order to prevent and treat properly associated comorbidities.

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med 2017; 376: 957-70. DOI: https://doi.org/10.1056/NEJMra1505557

Tillett W, Charlton R, Nightingale A, Snowball J, Green A, Smith C, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK clinical practice research Datalink with a hospital-based cohort. Rheumatology 2017; 56: 2109-13. DOI: https://doi.org/10.1093/rheumatology/kex323

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251-65.e19. DOI: https://doi.org/10.1016/j.jaad.2018.06.027

Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2018; 48: 28-34. DOI: https://doi.org/10.1016/j.semarthrit.2018.01.003

Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78. DOI: https://doi.org/10.1016/0049-0172(73)90035-8

Gottlieb AB, Merola JF. Axial psoriatic arthritis: an update for dermatologists. J Am Acad Dermatol 2021; 84: 92-101. DOI: https://doi.org/10.1016/j.jaad.2020.05.089

Coates LC, van der Horst-Bruinsma IE, Lubrano E, Beaver S, Drane E, Ufuktepe B, et al. Sex-specific differences in patients with psoriatic arthritis: a systematic review. J Rheumatol 2023; 50: 488-96. DOI: https://doi.org/10.3899/jrheum.220386

Menis J, Doussiere M, Touboul E, Barbier V, Sobhy-Danial JM, Fardellone P, et al. Current characteristics of a population of psoriatic arthritis and gender disparities. J Clin Transl Res 2023; 9: 84-92.

Van Kuijk AWR, Nurmohamed MT, Siebert S, Bergmans P, de Vlam K, Gremese E, et al.

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatology 2023; 62: 3382-90. DOI: https://doi.org/10.1093/rheumatology/kead089

Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis 2013; 72: 578-82. DOI: https://doi.org/10.1136/annrheumdis-2012-201357

Eder L, Chandran V, Gladman D. Gender-related differences in patients with psoriatic arthritis. Int J Clin Rheumtol 2012; 7: 641-9. DOI: https://doi.org/10.2217/ijr.12.63

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the corrona psoriatic arthritis/spondyloarthritis Registry. J Rheumatol 2018; 45: 1389-96. DOI: https://doi.org/10.3899/jrheum.171094

Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol 2022; 18: 513-26. DOI: https://doi.org/10.1038/s41584-022-00810-7

Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth 2013; 111: 52-8. DOI: https://doi.org/10.1093/bja/aet127

Lenert ME, Avona A, Garner KM, Barron LR, Burton MD. Sensory neurons, neuroimmunity, and pain modulation by sex hormones. Endocrinology 2021; 162: bqab109. DOI: https://doi.org/10.1210/endocr/bqab109

Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, et al. Women with psoriatic arthritis experience higher disease burden than men: findings from a real-world survey in the United States and Europe. J Rheumatol 2023; 50: 192-6. DOI: https://doi.org/10.3899/jrheum.220154

Wright GC, Kaine J, Deodhar A. Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum 2020; 50: 687-94. DOI: https://doi.org/10.1016/j.semarthrit.2020.05.005

Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum 2013; 65: 1213-23. DOI: https://doi.org/10.1002/art.37876

Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52. DOI: https://doi.org/10.1186/ar2670

Generali E, Sciré CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. Isr Med Assoc J 2016; 18: 203-8.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open 2018; 4: e000638. DOI: https://doi.org/10.1136/rmdopen-2017-000638

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol 2019; 46: 475-82. DOI: https://doi.org/10.3899/jrheum.171034

Albrecht K, Regierer AC, Strangfeld A, Marschall U, Callhoff J. High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex. RMD Open 2023; 9: e002960. DOI: https://doi.org/10.1136/rmdopen-2022-002960

Kamiya K, Ohtsuki M. Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020. J Dermatol 2023; 50: 12-25. DOI: https://doi.org/10.1111/1346-8138.16603

Haque N, Lories RJ, de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol 2016; 43: 376-82. DOI: https://doi.org/10.3899/jrheum.141359

Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract 2013; 2013: 580404. DOI: https://doi.org/10.1155/2013/580404

Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016; 37: 278-316. DOI: https://doi.org/10.1210/er.2015-1137

Rubin R. Postmenopausal women with a “normal” BMI might be overweight or even obese. JAMA 2018; 319: 1185-7. DOI: https://doi.org/10.1001/jama.2018.0423

Karlsson, T, Rask-Andersen M, Pan G, Höglund J, Wadelius C, Ek WE, et al. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. Nat Med 2019; 25: 1390-5. DOI: https://doi.org/10.1038/s41591-019-0563-7

Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia 2023; 66: 986-1002. DOI: https://doi.org/10.1007/s00125-023-05891-x

Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 2011; 63: 1729-35. DOI: https://doi.org/10.1002/acr.20627

Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based study. Arthritis Care Res 2017; 69: 51-7. DOI: https://doi.org/10.1002/acr.23094

Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211-6. DOI: https://doi.org/10.1136/annrheumdis-2011-201194

Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2015; 74: 813-7. DOI: https://doi.org/10.1136/annrheumdis-2013-204448

Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res 2011; 63: 195-202. DOI: https://doi.org/10.1002/acr.20363

Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology 2012; 51: 552-6. DOI: https://doi.org/10.1093/rheumatology/ker349

di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 2013; 65: 141-7. DOI: https://doi.org/10.1002/acr.21711

Klingberg E, Bilberg A, Bjorkman S, Hedberg M, Jacobsson L, Forsblad-d’Elia H, et al.

Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther 2019; 21: 17. DOI: https://doi.org/10.1186/s13075-019-1810-5

Landgren AJ, Jonsson CA, Bilberg A, Eliasson B, Torres L, Dehlin M, et al. Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention. Arthritis Res Ther 2023; 25: 131. DOI: https://doi.org/10.1186/s13075-023-03105-8

Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol 2019; 15: 461-74. DOI: https://doi.org/10.1038/s41584-019-0256-0

Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res 2017; 69: 67-74. DOI: https://doi.org/10.1002/acr.22926

Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis 2016; 75: 1680-6. DOI: https://doi.org/10.1136/annrheumdis-2015-207980

Maas AHEM, Appelman YEA. Gender differences in coronary heart disease. Neth Heart J 2010; 18: 598-602. DOI: https://doi.org/10.1007/s12471-010-0841-y

Charlton R, Green A, Shaddick G, Snowball J, Nightingale A, Tillett W, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology 2019; 58: 144-8. DOI: https://doi.org/10.1093/rheumatology/key286

Liu W, Ma W, Liu H, Li C, Zhang Y, Liu J, et al. Stroke risk in arthritis: a systematic review and meta-analysis of cohort studies. PLoS One 2021; 16: e0248564. DOI: https://doi.org/10.1371/journal.pone.0248564

Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S, Badley EM. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 2017; 76: 1396-404. DOI: https://doi.org/10.1136/annrheumdis-2016-210275

Karmacharya P, Crowson CS, Bekele D, Achenbach SJ, Davis JM, Ogdie A, et al. The epidemiology of psoriatic arthritis over five decades: a population-based study. Arthritis Rheumatol 2021; 73: 1878-85. DOI: https://doi.org/10.1002/art.41741

Haddad A, Saliba W, Lavi I, Batheesh A, Kasem S, Gazitt T, et al. The association of psoriatic arthritis with all-cause mortality and leading causes of death in psoriatic arthritis. J Rheumatol 2022; 49: 165-70. DOI: https://doi.org/10.3899/jrheum.210159

Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 2009; 36: 361-7. DOI: https://doi.org/10.3899/jrheum.080691

Ogdie A, Haynes K, Troxel AB, Love TJ, Hennessy S, Choi H, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: A longitudinal cohort study. Ann Rheum Dis 2014; 73: 149-53. DOI: https://doi.org/10.1136/annrheumdis-2012-202424

Colaco K, Widdifield J, Luo J, Rosen CF, Alhusayen R, Paterson JM, et al. Trends in mortality and cause specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. J Am Acad Dermatol 2021; 84: 1302-9. DOI: https://doi.org/10.1016/j.jaad.2020.10.031

Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-72. DOI: https://doi.org/10.1002/art.1780401021

Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007; 56: 2708-14. DOI: https://doi.org/10.1002/art.22800

Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63: 1182-9. DOI: https://doi.org/10.1002/art.30277

Fagerli KM, Kearsley-Fleet L, Mercer LK, Watson K, Packham J, Symmons DPM, et al. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. Rheumatology 2019; 58: 80-5. DOI: https://doi.org/10.1093/rheumatology/key241

Chaudhary H, Bohra N, Syed K, Donato A, Murad MH, Karmacharya P. All-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 2023; 75: 1052-65. DOI: https://doi.org/10.1002/acr.24820

Kerola AM, Kazemi A, Rollefstad S, Lillegraven S, Sexton J, Wibetoe G, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology 2022; 61: 4656-66. DOI: https://doi.org/10.1093/rheumatology/keac210

Shufelt CL, Pacheco C, Tweet MS, Miller VM. Sex-specific physiology and cardiovascular disease. Adv Exp Med Biol 2018; 1065: 433-54. DOI: https://doi.org/10.1007/978-3-319-77932-4_27

Chen Z, Xu Y, Chen M, Cui R, Wang YH, Dai SM, et al. Gout augments the risk of cardiovascular disease in patients with psoriasis: a population-based cohort study. Front Immunol 2021; 12: 703119. DOI: https://doi.org/10.3389/fimmu.2021.703119

Cai W, Duan XM, Liu Y, Yu J, Tang YL, Liu ZL, et al. Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway. BioMed Res Int 2017; 2017: 4391920. DOI: https://doi.org/10.1155/2017/4391920

Kim YH, Kim SI, Park B, Lee ES. Clinical characteristics of psoriasis for initiation of biologic therapy: a cluster analysis. Ann Dermatol 2023; 35: 132-9. DOI: https://doi.org/10.5021/ad.22.148

Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42. DOI: https://doi.org/10.1016/j.jaad.2008.01.006

Raadsen R, Hansildaar R, Pouw LC, Hooijberg F, Boekel L, Wolbink GJ, et al. Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated. RMD Open 2023; 9: e003485. DOI: https://doi.org/10.1136/rmdopen-2023-003485

Skov L, Thomsen SF, Kristensen LE, Dodge R, Hedegaard MS; Kjellber J. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br J Dermatol 2019; 180: 100-7. DOI: https://doi.org/10.1111/bjd.16919

Akhlaq A, Ali HF, Sheikh AB, Muhammad H, Ijaz SH, Sattar MH, et al. Cardiovascular diseases in the patients with psoriatic arthritis. Curr Probl Cardiol 2023; 48: 101131. DOI: https://doi.org/10.1016/j.cpcardiol.2022.101131

Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2020; 50: 1481-8. DOI: https://doi.org/10.1016/j.semarthrit.2020.02.001

Li GH, Cheung CL, Chung AK, Cheung BM, Wong IC, Fok MLY, et al. Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study. Psychol Med 2022; 52: 1765-76. DOI: https://doi.org/10.1017/S0033291720003566

Bucciarelli V, Caterino AL, Bianco F, Caputi CG, Salerni S, Sciomer S, et al. Depression and cardiovascular disease: the deep blue sea of women’s heart. Trends Cardiovasc Med 2020; 30: 170-6. DOI: https://doi.org/10.1016/j.tcm.2019.05.001

Agca R, Heslinga SC, Rollefstad S, Heslinga M, Mclinnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76: 17-28. DOI: https://doi.org/10.1136/annrheumdis-2016-209775

Arts EE, Popa C, den Broeder AA, Semb AG, Toms T, Kitas GD, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015; 74: 668-74. DOI: https://doi.org/10.1136/annrheumdis-2013-204024

Ernste FC, Sánchez-Menéndez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res 2015; 67: 1015-21. DOI: https://doi.org/10.1002/acr.22536

Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008, 29: 932-40. DOI: https://doi.org/10.1093/eurheartj/ehn018

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroidson cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-9. DOI: https://doi.org/10.1136/annrheumdis-2014-206624

Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med 2020; 17: e1003432. DOI: https://doi.org/10.1371/journal.pmed.1003432